Eli Lilly

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

Thirteen leading pharma companies released third-quarter 2020 financial results in October, and Japan’s Takeda (whose fiscal year ends in March) reported first-half numbers.

Leading the pack, bioMérieux’s quarterly sales soared 26.5% to $924 million, surpassing consensus estimates by 7%. The French diagnostics firm attributed the “exceptional momentum” to strong demand for its BioFire FilmArray testing solutions line and compatible Covid-19 tests. The company expects full-year sales…

The state of the hunt:

Regulators in Brazil, Canada and Europe commenced accelerated “rolling reviews” of AstraZeneca’s vaccine candidate even as the U.S. FDA widened its probe of the shot amid safety concerns.
  Serum Institute of India doubled its commitment of affordable Covid-19 vaccine doses to the COVAX AMC, pledging up to 200 million.
  The ACT Accelerator launched a partnership to provide 120 million Covid-19 rapid antigen tests to LMICs over six months.

 …

The state of the hunt:

Serum Institute of India inked a billion-dose deal to commercialize Novavax’s vaccine candidate in LMICs.
  SII will also collaborate with the Gates Foundation and Gavi to provide 100 million doses of an eventual vaccine to LMICs at $3 per dose or less.
  J&J will supply 100 million doses of its investigational vaccine to the U.S. as part of a $1 billion contract.

 

Vaccines

Clinical trials:

BioNTech and Fosun Pharma…

Twelve leading pharma companies released second-quarter 2020 financial results in July, and one Japanese firm (with a fiscal year ending in March) reported first-quarter numbers.

(Figures exclude exchange rate and portfolio changes where applicable.)

Leading the pack, AstraZeneca reported an 11% hike in total revenues to reach $6.3 billion in the quarter—slightly above consensus estimates. Amid the coronavirus lockdown, the British drugmaker saw strong product sales as its…

The state of the hunt:

The EU is reportedly weighing abstention from the COVAX Facility due to vaccine pricing and timing concerns.
  An inhaled interferon drug produced extraordinary Phase 2 data in a study some critics have faulted.
  Vaccines from AstraZeneca-Oxford University, CanSino, and Pfizer-BioNTech had positive Phase 1/2 or Phase 2 news.

 

Vaccines

Clinical trials:

The Lancet published preliminary Phase 1/2 results Monday showing the…

The state of the hunt:

China’s Sinovac and CNBG separately touted preliminary Phase 1/2 results for inactivated vaccine candidates—with favorable safety and immunogenicity profiles for both.
  Teams in China, Germany, Japan, South Korea, Russia and the United Kingdom are set to begin first-in-human clinical trials for six different investigational vaccines.
  Commonly available steroid dexamethasone reduced mortality in Covid-19 patients requiring respiratory support, an…

Thirteen leading pharma companies released first-quarter 2020 financial results in April. Covid-19 dominated the reports, spurring short-term sales gains for many companies while generating longer-term uncertainty about the duration and impact of the pandemic. Ahead of the reports, some analysts had drastically lowered estimates in anticipation of a slowdown in routine medical procedures.

(Figures exclude exchange rate and portfolio changes where applicable.)

Leading the…


The state of the hunt: 

Chinese developers now have three vaccine candidates in clinical trials. Gilead’s antiviral remdesivir looked anecdotally more promising this week after STAT reported favorable patient outcomes in a Chicago hospital involved in its Phase 3 trials. STAT Further bolstering remdesivir, the U.S. National Institutes of Health issued a press release today touting a preprint government study that found the drug “reduced clinical disease” and lung damage in rhesus…


The state of the hunt: 

China’s CanSino is closing in on a vaccine, with its adenovirus viral vector-based Ad5-nCoV shot advancing to Phase 2, according to a disclosure filed yesterday. Gilead’s remdesivir remains a top contender among investigational therapies: the company has expanded its two Phase 3 trials of the drug from 1,000 to 4,000 enrollees. Hydroxychloroquine is now the subject of over 60 Covid-19 trials, according to ClinicalTrials.gov.

 

Vaccines